Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Ireland

Research and Innovation Action · Running

INSPIRE Developing novel inhaled bioengineered Extracellular Vesicle RNA based advanced therapeutics, delivered by tailored aerosol delivery technology for the treatment of lung cancer

Coordinator
Myriad Consulting Limited, Ireland
Runs
1 June 2022 to 28 February 2026
Status
Running
EU funding
€13.3m
Total cost
€13.3m
Partners
9 organisations in 4 countries
Type
Research and Innovation Action
Grant agreement
101057777

What the project is doing

In the project's own words, from its summary on CORDIS.

Lung cancer (LC) treatments have advanced in recent years with the advent of genetic profiling and immunotherapy. However, LC is a complex heterogeneous disease and survival rates remain poor. RNA (mRNA, microRNA, other non-coding RNAs and nucleic acid based modulators of same) and gene therapies (DNA or gene editing) for delivering nucleic acid-based therapeutics have curative potential for a host of indications previously untreatable.

They have yet to enter the mainstream, due to safety concerns and difficulties delivering them efficiently to areas other than the liver, kidney and circulatory system. Aerosol delivery allows direct targeting of lung tissues but viscous mucus in the lung is a significant barrier to gene transfer to the target cells of the lungs. Even if the mucus layer can be penetrated, inefficient penetration through the cell membrane further impedes access of these vectors to the underlying target cells, thus preventing successful gene transfer.

Delivery is a major barrier to successful pulmonary gene therapy for competing viral and non-viral gene transfer vectors and the vast promise of gene therapy has many challenges to overcome. OMNI's novel solution is pioneering the use of genetically modified MSC EVs with a proprietary surface engineering technology to further enhance delivery through the mucus barrier and into the targeted lung cells. This platform technology also combines efficient aerosol delivery of the EVs via AERO's proprietary state of the art vibrating mesh nebulizer technology.

This unique solution solves the problems associated with lung targeted delivery of RNA based advanced therapies.

Topics

Who is involved

OrganisationCityCountryRole
Myriad Consulting LimitedDublinIrelandCoordinator
Deutsches Krebsforschungszentrum HeidelbergHeidelbergGermanyParticipant
Pharmalex GmbHBad Homburg V. D. HoheGermanyParticipant
EverzomParisFranceParticipant
Aerogen LtdGalwayIrelandParticipant
Omnispirant LimitedClonmel TipperaryIrelandParticipant
Remedy Biologics LimitedGalwayIrelandParticipant
The Provost, Fellows, Foundation Scholars & the Other Members of Board, of the College of the Holy & Undivided Trinity of Queen Elizabeth Near DublinDublinIrelandParticipant
Cellularis Biomodels LdaIlhavoPortugalParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI